title: Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities.
abstract: This retrospective study was undertaken to obtain information regarding the survival and toxicities after Yttrium-90 microspheres treatment in patients with primary liver malignancies. Baseline, treatment, and follow-up data were collected and analyzed for 21 patients treated with Yttrium-90 microspheres. Survival analysis was then performed. The results of this study showed that median survival for all the patients was 120 days. Twenty of 21 patients were categorized as high-risk with a median survival of 114 days. It was also found that one high-risk patient has survived 858 days with no recurrence of disease. Acute grade 3-5 toxicities were recorded for nine patients and consisted of elevations in AST and bilirubin, thrombocytopenia, abdominal pain, ascites, nausea, fatigue, and death. This study concluded that Yttrium-90 is a low-toxicity, outpatient alternative for individuals with liver cancer and without many options. The maximal value, however, may lie in the treatment of low-risk patients.
authors.affiliation: Department of Radiation Oncology, University of Virginia, Charlottesville, VA 22908-0383, USA.
authors.forename: Kelli A
authors.initials: KA
authors.lastname: Reardon
authors.forename: Alyson F
authors.initials: AF
authors.lastname: McIntosh
authors.forename: A Tanner
authors.initials: AT
authors.lastname: Shilling
authors.forename: Klaus D
authors.initials: KD
authors.lastname: Hagspiel
authors.forename: Abdullah
authors.initials: A
authors.lastname: Al-Osaimi
authors.forename: Carl
authors.initials: C
authors.lastname: Berg
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Caldwell
authors.forename: Patrick G
authors.initials: PG
authors.lastname: Northup
authors.forename: Fritz
authors.initials: F
authors.lastname: Angle
authors.forename: Robert
authors.initials: R
authors.lastname: Mulder
authors.forename: Tyvin A
authors.initials: TA
authors.lastname: Rich
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006760:Hospitalization; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D012189:Retrospective Studies; D015021:Yttrium Radioisotopes / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D015021:Yttrium Radioisotopes